Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
WALTHAM, Mass., March 01, 2017 -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that its President and Chief Executive Officer, Mark Fitzpatrick, and SVP, Medical and Clinical Affairs, William Ludlam, will present at the Cowen and Company’s 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 8:40 a.m. ET.
A live and archived audio webcast of the presentation will be available under the News & Investors section of Chiasma’s website at www.ChiasmaPharma.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
About Chiasma
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The company is conducting an international Phase 3 clinical trial of octreotide capsules (conditionally trade-named “Mycapssa®”) for the maintenance treatment of adult acromegaly patients to support a potential submission of a Marketing Authorization Application to the European Medicines Agency. Chiasma received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 15, 2016 regarding its New Drug Application (NDA) for Mycapssa in the United States. Chiasma is headquartered in the United States with a wholly owned subsidiary in Israel. Mycapssa and TPE are registered trademarks of Chiasma.
Contact: Cammy Duong MacDougall Biomedical Communications (781) 591-3443 [email protected]
